Breaking News Instant updates and real-time market news.

DLPH

Delphi

$64.86

1.42 (2.24%)

, SSNLF

Samsung

13:57
11/30/16
11/30
13:57
11/30/16
13:57

Battleground: Analysts split if Delphi sinks or swims as cars go electric

A pair of Wall Street research firms are split on whether automotive supplier Delphi (DLPH) will thrive or struggle amid trends toward electric and connected vehicles, with Morgan Stanley critical of the company's exposure to traditional combustion cars and Jefferies highlighting its on-trend businesses and the unique strength of its well-developed manufacturer relationships. The divergent views come as Delphi itself announced a tie-up with Intel (INTC) this week, leveraging the semiconductor giant's chips to accelerate its self-driving car project. MORGAN STANLEY SAYS SELL: Morgan Stanley's Adam Jonas downgraded Delphi to Underweight and cut his price target to $59 from $74 Tuesday, arguing that the ongoing shift towards electric vehicles isn't something that existing equipment manufacturers and suppliers "can easily cope with." The analyst adds that EV trends, which are coming during an already "sensitive point" in the auto cycle, will not just reduce demand for gasoline powertrains but also mandate increased R&D costs from incumbent suppliers while elevating "hungry" new competitors from the consumer electronics industry, such as a Samsung (SSNLF) or Foxconn (HNHPF). Net-net, Jonas sees "emerging risk" for even the best suppliers, particularly those with meaningful exposure to the internal combustion ecosystem, who will confront "unprecedented pressures" to re-engineer propulsion systems. On Delphi in particular, the analyst notes that its powertrain business accounts for roughly 25% of global profits, and while he cautions that those products won't be dropped immediately, Jonas does see "scope for diminished economic returns" and "material risk to the company's earnings trajectory." The analyst notes that the electrification concerns are also reflected in Morgan Stanley's Underweight rating on BorgWarner (BWA) and its recent downgrade of Continental (CTTAY). JEFFERIES SEES DELPHI AS SUPPLIER OF FUTURE: Jefferies analyst David Kelley initiated Delphi coverage with a Buy rating and $80 target Wednesday, saying its scale, expertise, and manufacturer relationships make it "best positioned" among the firm's coverage universe to supply the ongoing mobility innovation cycle through 2025. Labeling the company "built to leverage global auto evolution," Kelley forecasts 13% annual comp growth for its Electronics and Safety business segment amid "rapid" industrywide adoption of driver assistance technologies, while its Powertrain segment "should benefit" from tightening emissions regulations. The analyst also sees a "continued margin expansion opportunity" due to an expected product mix shift towards vehicle software, and says new players in the evolving auto landscape could be targeted as attractive bolt-on acquisitions for Delphi. DELPHI ADDS INTEL TO SELF-DRIVING PROJECT: At a press event Tuesday, Delphi and Mobileye (MBLY) announced that Intel (INTC) is joining their existing technology collaboration, providing high-speed chips for their self-driving vehicle kit slated to be unveiled at this January's Consumer Electronics Show ahead of a 2019 launch. "For us, it's a big step forward because it allows us to really accelerate the development of the overall program," Delphi executive Glen De Vos said of the Intel partnership, according to media reports. PRICE ACTION: Having dipped more than 4% yesterday after Morgan Stanley's ratings cut, shares of Delphi have rebounded about 2% to $64.66 in afternoon trading.

DLPH

Delphi

$64.86

1.42 (2.24%)

SSNLF

Samsung

HNHPF

Hon Hai Precision

BWA

BorgWarner

$35.91

1.45 (4.21%)

CTTAY

Continental AG

$35.68

1.015 (2.93%)

INTC

Intel

$35.31

-0.2 (-0.56%)

MBLY

Mobileye

$37.49

-0.05 (-0.13%)

  • 08

    Dec

  • 14

    Dec

  • 10

    Jan

DLPH Delphi
$64.86

1.42 (2.24%)

11/29/16
11/29/16
DOWNGRADE
Target $59

Underweight
Delphi downgraded to Underweight on electrification risk at Morgan Stanley
As previously reported, Morgan Stanley downgraded Delphi to Underweight from Equal Weight and lowered its price target to $59 from $75. Analyst Adam Jonas believes an acceleration of electric vehicle strategy by Delphi's OEM customers will negatively impact growth, lower margins for ICE powertrain, and result in greater up-front RD&E costs. The analyst sees diminishing economic returns given changing OEM priorities to re-engineer propulsion systems to electric from internal combustion, creating material earnings growth risk.
11/29/16
MSCO
11/29/16
DOWNGRADE
MSCO
Underweight
Delphi downgraded to Underweight from Equal Weight at Morgan Stanley
11/30/16
JEFF
11/30/16
INITIATION
Target $80
JEFF
Buy
Delphi initiated with a Buy at Jefferies
Jefferies analyst David Kelley initiated Delphi with a Buy rating, calling it the best positioned in its group to benefit from drivers of mobility innovation, accelerating vehicle electrification and increased software content. Kelley set an $80 price target on Delphi shares.
11/22/16
BREN
11/22/16
INITIATION
Target $70
BREN
Hold
Delphi initiated with a Hold at Berenberg
Target $70.
SSNLF Samsung

11/01/16
BMUR
11/01/16
NO CHANGE
Target $25
BMUR
Buy
Integrated Device continues to push through rough patch, says Brean Capital
Brean Capital analyst Mike Burton noted Integrated Device (IDTI) reported relatively in-line Q1 results and gave mixed guidance as the company is being impacted by Samsung's (SSNLF) Note 7 recall. The analyst believes the company is working through its rough patch and executing well on the margin and cost side of its business model. Burton reiterated his Buy rating and raised his price target to $25 from $23 on Integrated Device shares.
10/18/16
UBSW
10/18/16
NO CHANGE
Target $127
UBSW
Buy
Apple near-term outlook improved, says UBS
UBS analyst Steven Milunovich believe Apple's (AAPL) Q4 guidance could have upside due to an extra week in the quarter and checks that show iPhone 7 demand is a bit better than the iPhone 6s. The analyst also noted the Samsung (SSNLF) Note 7 problem remains a wild card, but believes it should help Apple's retention rate. Milunovich said the current Apple share price reflects a gradual erosion of its installed base and the amount people are willing to spend with Apple, which he believes is conservative. Milunovich reiterated his Buy rating and $127 price target on Apple shares.
10/26/16
NEED
10/26/16
NO CHANGE
Target $150
NEED
Strong Buy
Needham recommends buying Apple on Pokemon Go, Samsung upside
Following Apple's (AAPL) Q4 results, Needham analyst Laura Martin notes that iPhone revenue rose driven in part by Samsung's (SSNLF) Galaxy Note 7 imploding in September and estimates $10B-$20B of brand value transfers to Apple during the next adoption cycle owing to Samsung's poor handling of the replacement, recall and ultimate discontinuation of the Note 7. Of the company's extra services revenue quarter over quarter, the analyst's channel checks indicate that Niantic and Nintendo's (NTDOY) Pokemon Go represented much of the growth. Martin reiterates a Strong Buy and $150 price target on Apple's shares.
11/01/16
ADAM
11/01/16
NO CHANGE
Target $13
ADAM
Buy
DSP Group long-term thesis remains on track, says Canaccord
Canaccord analyst Matthew Ramsay noted DSP Group (DSPG) reported strong September results driven by record revenue in new product categories. The analyst noted new design wins and said the company is well positioned to yield a return to solid sales growth at higher margins and has the financial position to secure business with large customers. Ramsay reiterated his Buy rating but lowered his price target to $13 from $14 based on the Samsung (SSNLF) Note 7 cancellation.
HNHPF Hon Hai Precision

BWA BorgWarner
$35.91

1.45 (4.21%)

11/22/16
BREN
11/22/16
INITIATION
Target $28
BREN
Sell
BorgWarner initiated with a Sell at Berenberg
Target $28.
11/09/16
11/09/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. JPMorgan (JPM) downgraded to Neutral from Outperform at Baird with analyst David George noting the stock's outperformance and the higher re-rating of its valuation multiple. 2. GoPro (GPRO) downgraded to Neutral from Outperform at Wedbush, to Market Perform from Outperform at Raymond James, and to Sell from Neutral at Dougherty. 3. Universal Health (UHS) downgraded to Neutral from Buy at BofA/Merrill, to Neutral from Buy at Mizuho, and to Market Perform from Outperform at Avondale. 4. Globus Medical (GMED) downgraded to Market Perform from Outperform at JMP Securities, to Perform from Outperform at Oppenheimer, and to Market Perform from Outperform at William Blair. 5. Delphi (DLPH) and Magna (MGA) were downgraded to Underperform from Buy at BofA/Merrill while the firm downgraded Lear (LEA), American Axle (AXL), Adient (ADNT), and BorgWarner (BWA) to Underperform from Neutral. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/30/16
JEFF
11/30/16
INITIATION
Target $43
JEFF
Buy
BorgWarner initiated with a Buy at Jefferies
Jefferies analyst David Kelley initiated BorgWarner with a Buy rating, saying turbochargers remain a growth driver while the company's new technology acquisition and mix shift position it for penetration in hybrid/electric vehicles. Kelley sets a $43 price target on BorgWarner shares.
11/30/16
11/30/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Shutterfly (SFLY) initiated with a Buy at Aegis. 2. WageWorks (WAGE) initiated with a Buy at Chardan. 3. BorgWarner (BWA) initiated with a Buy at Jefferies. 4. Advaxis (ADXS) initiated with a Buy at Cantor. 5. Xtant (XTNT) initiated with a Buy at Aegis. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CTTAY Continental AG
$35.68

1.015 (2.93%)

11/29/16
JEFF
11/29/16
INITIATION
JEFF
Buy
Continental AG initiated with a Buy at Jefferies
Price target EUR 190.
11/22/16
BREN
11/22/16
INITIATION
BREN
Sell
Continental AG initiated with a Sell at Berenberg
Price target EUR 140.
07/06/16
LEHM
07/06/16
UPGRADE
LEHM
Overweight
Continental AG upgraded to Overweight from Equal Weight at Barclays
10/14/16
LEHM
10/14/16
DOWNGRADE
LEHM
Equal Weight
Continental AG downgraded to Equal Weight from Overweight at Barclays
INTC Intel
$35.31

-0.2 (-0.56%)

11/29/16
BARD
11/29/16
NO CHANGE
Target $42
BARD
Outperform
Notebook trends bode well for Intel, says Baird
Baird analyst Tristan Gerra said recent notebook trends bodes well for Intel. The analyst expects revenues to be within the guidance range but above the midpoint. Additional catalysts include an ongoing stabilization off PC units and a continued mix shift towards data center. Gerra reiterated his Outperform rating and $42 price target on Intel shares.
11/22/16
MKMP
11/22/16
NO CHANGE
MKMP
Buy
MKM Partners raises NVIDIA, AMD price targets on inflecting semi opportunities
MKM Partners analyst Ian Ing raised his price target for NVIDIA (NVDA) to $106 from $87, saying that thematic attention is heating up as large suppliers are crowding into artificial intelligence as an investment theme with non-GPU solutions. While other suppliers may be able to come up with better performance-for-power in certain use cases, he believes NVIDIA GPUs still have user stickiness with developer incumbency and easy-to-use tools that will be difficult to overcome. The analyst also raised his price target for AMD (AMD) to $10.50 from $8 to reflect improved prospects for the company driven by new product pipeline. Although Ian expects AMD to be a relatively minor player, its shares are helped by continued A.I. headlines and NVIDIA, Intel (INTC), and Qualcomm (QCOM) turning increasingly vocal on the opportunity. He reiterates a Buy rating on NVIDIA and AMD shares.
11/25/16
MACQ
11/25/16
NO CHANGE
Target $20
MACQ
Underperform
Intel leaving wearables would hurt Fossil, says Macquarie
According to media reports, Intel (INTC) is potentially exiting the wearable space, Macquarie analyst Laurent Vasilescu tells investors in a research note. In addition, Intel's wearable brand Basis is shutting down as of December 31, the analyst adds. He sees "important negative ramifications" for Fossil Group (FOSL) since Intel is the hardware component provider for the company's wearable initiative. Fossil depends on Intel's hardware knowhow for wearables, Vasilescu contends. The analyst has an Underperform rating on Fossil with a $20 price target.
10/19/16
PACS
10/19/16
NO CHANGE
PACS
Intel Q4 PC commentary negative for Marvell, others resilient says Pacific Crest
Pacific Crest notes that Intel (INTC) said its PC customers are poised to reduce their inventories in Q4. The firm says that the comment is negative for Marvell (MRVL). However, the firm believes that Advanced Micro Devices (AMD), NVIDIA (NVDA), ON Semiconductor (ON) and Synaptics (SYNA) are "most resilient" to this development, given their share gains, growth and other factors.
MBLY Mobileye
$37.49

-0.05 (-0.13%)

11/16/16
BARD
11/16/16
NO CHANGE
Target $61
BARD
Outperform
Mobileye remains a top idea, says Baird
Baird analyst David Leiker said Mobileye remains a top idea following strong Q3 results and positive new contract announcements. The analyst noted shares were down probably due to lack of a final REM agreement, but management said they expect one in the imminent future, which should be a catalyst that will support a higher stock price over the next couple of months. Leiker reiterated his Outperform rating and raised his price target to $61 from $58 on Mobileye shares.
11/17/16
WELS
11/17/16
NO CHANGE
WELS
Mobileye shares should be bought on weakness, says Wells Fargo
Wells Fargo says that yesterday's decline in Mobileye's stock was unwarranted. The firm expects Mobileye to announce a deal with Volkswagen very soon ,and it expects Mobileye to unveil several other deals with OEMs in 2017. The firm recommends buying the stock on weakness, and it keeps an Outperform rating on the shares.
11/15/16
BARD
11/15/16
NO CHANGE
Target $61
BARD
Outperform
Mobileye price target raised to $61 from $58 at Baird
Baird analyst David Leiker raised his price target for Mobileye to $61 following the company's Q3 results. The analyst keeps an Outperform rating on the shares.
11/16/16
RHCO
11/16/16
NO CHANGE
RHCO
Mobileye should be bought on weakness, says SunTrust
After Mobileye reported slightly stronger than expected Q3 results and provided in-line Q4 EPS guidance, SunTrust analyst William Stein calls the company's results "imperfect." The analyst says that the company's results were hurt by "temporary blips" that will be "overwhelmed" by deals that it's poised to announce soon. He keeps a $63 price target and a Buy rating on the shares.

TODAY'S FREE FLY STORIES

SEAS

SeaWorld

$15.65

-0.16 (-1.01%)

20:01
06/25/17
06/25
20:01
06/25/17
20:01
Hot Stocks
SeaWorld receives subpoenas, forms special committee over 'Blackfish' statements »

SeaWorld stated in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$155.07

1.67 (1.09%)

19:57
06/25/17
06/25
19:57
06/25/17
19:57
Periodicals
Facebook plans to offer TV-quality content by late summer, WSJ says »

Facebook is in talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

FRO

Frontline

$5.59

0.08 (1.45%)

, GNRT

Gener8 Maritime

$6.12

0.21 (3.55%)

19:50
06/25/17
06/25
19:50
06/25/17
19:50
Periodicals
Frontline abandons plans to buy Gener8, WSJ says »

Frontline (FRO) has…

FRO

Frontline

$5.59

0.08 (1.45%)

GNRT

Gener8 Maritime

$6.12

0.21 (3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$84.83

0.4 (0.47%)

18:46
06/25/17
06/25
18:46
06/25/17
18:46
Hot Stocks
Third Point confirms $3.5B stake in Nestle, urges change at company »

In a letter published…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Wal-Mart

$74.84

-0.68 (-0.90%)

18:23
06/25/17
06/25
18:23
06/25/17
18:23
Periodicals
Wal-Mart initially clamped down on alcohol, swearing at Jet.com, WSJ says »

After Wal-Mart acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$965.59

8.5 (0.89%)

, GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

17:55
06/25/17
06/25
17:55
06/25/17
17:55
Periodicals
EU plans EUR1B fine against Google this week, FT reports »

The EU plans to levy a…

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

NSRGY

Nestle

$84.83

0.4 (0.47%)

17:37
06/25/17
06/25
17:37
06/25/17
17:37
Periodicals
Dan Loeb's Third Point targets Nestle, Bloomberg says »

Nestle is being targeted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNG

Cheniere Energy

$47.62

0.34 (0.72%)

17:27
06/25/17
06/25
17:27
06/25/17
17:27
Hot Stocks
Cheniere Energy announces commencement of Korea Gas LNG contract »

Cheniere Energy and Korea…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIA

Viacom

$39.15

0.1 (0.26%)

, VIAB

Viacom

$34.11

-0.01 (-0.03%)

16:20
06/25/17
06/25
16:20
06/25/17
16:20
Hot Stocks
Box Office Battle: Fifth 'Transformers' film ekes out $45M in franchise low »

Viacom's (VIA)…

VIA

Viacom

$39.15

0.1 (0.26%)

VIAB

Viacom

$34.11

-0.01 (-0.03%)

TWX

Time Warner

$99.70

0.3 (0.30%)

DIS

Disney

$104.36

0.14 (0.13%)

LGF.A

Lionsgate

$27.07

0.31 (1.16%)

LGF.B

Lionsgate

$25.38

0.34 (1.36%)

FOX

21st Century Fox

$26.93

0.3 (1.13%)

FOXA

21st Century Fox

$27.19

0.22 (0.82%)

SNE

Sony

$38.52

0.11 (0.29%)

CMCSA

Comcast

$39.50

-0.44 (-1.10%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 27

    Jul

  • 03

    Aug

  • 08

    Aug

GSK

GlaxoSmithKline

$44.29

0.13 (0.29%)

14:42
06/25/17
06/25
14:42
06/25/17
14:42
Hot Stocks
GlaxoSmithKline granted Orphan designation for multiple myeloma treatment »

The FDA granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$25.33

-0.13 (-0.51%)

14:40
06/25/17
06/25
14:40
06/25/17
14:40
Hot Stocks
Biohaven granted Orphan designation for Rett syndrome treatment »

The FDA granted Biohaven…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESALY

Eisai

$56.42

-0.075 (-0.13%)

14:37
06/25/17
06/25
14:37
06/25/17
14:37
Hot Stocks
Eisai unit receives Orphan designation for myelomonocytic leukemia treatment »

The FDA has granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTNR

Partner Communications

$5.25

0.1123 (2.19%)

14:23
06/25/17
06/25
14:23
06/25/17
14:23
Hot Stocks
Partner Communications executes early loan repayments, sees Q2 expense »

Partner Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RARX

RA Pharmaceuticals

$23.01

0.01 (0.04%)

14:21
06/25/17
06/25
14:21
06/25/17
14:21
Hot Stocks
RA Pharma: Presentation on complement inhibitors supports continued development »

Ra Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

VSTM

Verastem

$2.32

-0.06 (-2.52%)

14:17
06/25/17
06/25
14:17
06/25/17
14:17
Hot Stocks
Verastem reports long-term follow up data from 'DYNAMO' study »

Verastem announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 29

    Jun

  • 11

    Jul

BMY

Bristol-Myers

$56.64

-0.69 (-1.20%)

14:09
06/25/17
06/25
14:09
06/25/17
14:09
Hot Stocks
Bristol-Myers reports four-year follow up data from 'ELOQUENT-2' study »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 24

    Sep

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

, CELG

Celgene

$134.31

0.63 (0.47%)

14:05
06/25/17
06/25
14:05
06/25/17
14:05
Hot Stocks
Agios Pharmaceuticals reports new data from Phase 1/2 trial of IDHIFA »

Agios Pharmaceuticals…

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

CELG

Celgene

$134.31

0.63 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

14:00
06/25/17
06/25
14:00
06/25/17
14:00
Hot Stocks
Agios reports updated Phase 2 data on AG-348, sees 1H18 pivotal program »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNOW

Intrawest Resorts

$23.65

0.04 (0.17%)

13:53
06/25/17
06/25
13:53
06/25/17
13:53
Hot Stocks
Intrawest Resorts says Hart-Scott-Rodino merger waiting period expires »

Intrawest Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$169.61

-1.07 (-0.63%)

13:31
06/25/17
06/25
13:31
06/25/17
13:31
Periodicals
Cigna could gain over 15% by end of next year, Barron's says »

The GOP healthcare plan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$48.03

0.53 (1.12%)

, NKE

Nike

$52.85

0.45 (0.86%)

13:26
06/25/17
06/25
13:26
06/25/17
13:26
Periodicals
Potential Nike-Amazon deal another negative for Foot Locker, Barron's says »

A potential direct-sale…

FL

Foot Locker

$48.03

0.53 (1.12%)

NKE

Nike

$52.85

0.45 (0.86%)

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 29

    Jun

RHT

Red Hat

$99.42

0.54 (0.55%)

13:15
06/25/17
06/25
13:15
06/25/17
13:15
Periodicals
Red Hat may eke out double-digit returns, Barron's says »

Red Hat investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$126.07

-0.16 (-0.13%)

, UTHR

United Therapeutics

$131.59

-0.11 (-0.08%)

13:01
06/25/17
06/25
13:01
06/25/17
13:01
Periodicals
Alexion, United Therapeutics worth a look, Barron's says »

After the recent jump in…

ALXN

Alexion

$126.07

-0.16 (-0.13%)

UTHR

United Therapeutics

$131.59

-0.11 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 23

    Oct

AIZ

Assurant

$101.25

0.99 (0.99%)

12:32
06/25/17
06/25
12:32
06/25/17
12:32
Periodicals
Assurant could double as investors reevaluate company, Barron's says »

Assurant is shifting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCR

NCR Corp.

$38.64

0.09 (0.23%)

12:27
06/25/17
06/25
12:27
06/25/17
12:27
Periodicals
NCR Corp. could gain 30% in a year, Barron's says »

Shares of NCR Corp. could…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.